» Articles » PMID: 10826506

Protection of Ischemic Rat Heart by Dantrolene, an Antagonist of the Sarcoplasmic Reticulum Calcium Release Channel

Overview
Date 2000 May 29
PMID 10826506
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Cytosolic Ca2+ overload plays a major role in the development of irreversible injury during myocardial ischemia. Such overload is due at least in part to the release of Ca2+ from the sarcoplasmic reticulum. Therefore, we investigated whether dantrolene, a blocker of the sarcoplasmic reticulum Ca2+ release channel, may protect from ischemic injury. In binding experiments, we determined the effect of dantrolene on [3H]-ryanodine binding in rat cardiac tissue. In perfusion experiments, isolated rat hearts were perfused for 20 min in the working mode, in the presence of 0-45 microM dantrolene. The hearts were then subjected to 30 min of global ischemia and 120 min of retrograde reperfusion. Tissue injury was evaluated on the basis of triphenyltetrazolium chloride (TTC) staining and LDH release. The binding experiments showed that dantrolene displaced 4 nM [3H]-ryanodine with IC50 of 34 microM. In the perfusion experiments, tissue necrosis (i.e., TTC-negative tissue) averaged 28.3 +/- 1.6% of the ventricular mass under control conditions. Dantrolene was protective at micromolar concentrations: tissue necrosis decreased to 21.4 +/- 1.0% and 8.4 +/- 1.4% with 1 microM and 45 microM dantrolene, respectively (P < 0.05 and P < 0.01). Similar results were obtained with regard to LDH release. At low concentrations (up to 4 microM), dantrolene did not produce any significant hemodynamic effect, except for a slight increase in coronary flow, whereas at higher concentration a negative inotropic effect was apparent. In conclusion, dantrolene reduced ischemic injury even at concentrations that did not affect contractile performance. Modulation of sarcoplasmic reticulum Ca2+ release might represent a new cardioprotective strategy.

Citing Articles

Could dantrolene be explored as a repurposed drug to treat COVID-19 patients by restoring intracellular calcium homeostasis?.

Jiang B, Liang S, Liang G, Wei H Eur Rev Med Pharmacol Sci. 2020; 24(19):10228-10238.

PMID: 33090434 PMC: 7702195. DOI: 10.26355/eurrev_202010_23247.


Functional recovery after dantrolene-supplementation of cold stored hearts using an ex vivo isolated working rat heart model.

Villanueva J, Gao L, Chew H, Hicks M, Doyle A, Qui M PLoS One. 2018; 13(10):e0205850.

PMID: 30312353 PMC: 6185861. DOI: 10.1371/journal.pone.0205850.


Ablation of phospholamban rescues reperfusion arrhythmias but exacerbates myocardium infarction in hearts with Ca2+/calmodulin kinase II constitutive phosphorylation of ryanodine receptors.

Valverde C, Mazzocchi G, Di Carlo M, Ciocci Pardo A, Salas N, Ragone M Cardiovasc Res. 2018; 115(3):556-569.

PMID: 30169578 PMC: 6383052. DOI: 10.1093/cvr/cvy213.


SUMO-Modified FADD Recruits Cytosolic Drp1 and Caspase-10 to Mitochondria for Regulated Necrosis.

Choi S, Kim H, Jeong E, Lee H, Park S, Lee S Mol Cell Biol. 2016; 37(2).

PMID: 27799292 PMC: 5214857. DOI: 10.1128/MCB.00254-16.


Discrepancy in calcium release from the sarcoplasmic reticulum and intracellular acidic stores for the protection of the heart against ischemia/reperfusion injury.

Khalaf A, Babiker F J Physiol Biochem. 2016; 72(3):495-508.

PMID: 27325083 DOI: 10.1007/s13105-016-0498-0.